Bereich
Brustzentrum St.Gallen
BZ · Dept. IV
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts
von Moos R, Lademann J, Lacouture M, Dummer R, Lorusso D, Scotte F, Sehouli J, Harrold K, Rayson D, Aapro M, Thürlimann B, Hauschild A. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. EJO 2008; 44:781-90.
01.04.2008Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts
01.04.2008EJO 2008; 44:781-90
von Moos Roger, Lademann Jürgen, Lacouture Mario E, Dummer Reinhard, Lorusso Domenica, Scotte Florian, Sehouli Jalid, Harrold Karen, Rayson Daniel, Aapro Matti, Thürlimann Beat, Hauschild Axel
Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study
Strasser F, Demmer-Steingruber R, Böhme C, Schmitz S, Thürlimann B, Cerny T, Gillessen Sommer S. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. The Oncologist 2008; 13:337-46.
01.03.2008Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study
01.03.2008The Oncologist 2008; 13:337-46
Strasser Florian, Demmer-Steingruber Ruth, Böhme Christel, Schmitz Shu-Fang Hsu, Thürlimann Beat, Cerny Thomas, Gillessen Sommer Silke
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Aapro M, Saad F, Rizzoli R, Paterson A, Monnier A, Lipton A, Jonat W, Hortobagyi G, Hadji P, Gralow J, Gnant M, Dirix L, Crinò L, Costa L, Colomer R, Coleman R, Body J, Abrahamsson P, Thürlimann B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19:420-32.
01.03.2008Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
01.03.2008Ann Oncol 2008; 19:420-32
Aapro M, Saad F, Rizzoli R, Paterson A H G, Monnier A, Lipton A, Jonat W, Hortobagyi G N, Hadji P, Gralow J, Gnant M, Dirix L, Crinò L, Costa L, Colomer R, Coleman R E, Body J J, Abrahamsson P A, Thürlimann Beat
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
Hess V, Scheithauer W, Figer A, Saletti P, Bajetta E, Ruhstaller T, Bodoky G, Dietrich D, Grawe P, Glimelius B, Herrmann R. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. The lancet oncology 2008; 9:132-8.
01.02.2008CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
01.02.2008The lancet oncology 2008; 9:132-8
Hess Viviane, Scheithauer Werner, Figer Arie, Saletti Piercarlo, Bajetta Emilio, Ruhstaller Thomas, Bodoky György, Dietrich Daniel, Grawe Philipp, Glimelius Bengt, Herrmann Richard
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
von Minckwitz G, Kaufmann M, Mehta K, Loibl S, Skacel T, Vescia S, Grasshoff S, Jackisch C, Costa S, Huober J, Hilfrich J, Gerber B, Eidtmann H, Eiermann W, du Bois A, Kümmel S, German Breast Group. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:292-8.
01.02.2008Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
01.02.2008Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:292-8
von Minckwitz G, Kaufmann M, Mehta K M, Loibl S, Skacel T, Vescia S, Grasshoff S-T, Jackisch C, Costa S D, Huober Jens, Hilfrich J, Gerber B, Eidtmann H, Eiermann W, du Bois A, Kümmel S, German Breast Group
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
Strasser F, Cerny T, Von Moss R, Brändle M, Holst B, Kaufmann K, Tschöp M, Büche D, Thürlimann B, Maeder M, Lutz T, Demmer-Steingruber R. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. BJC 2008; 98:300-8.
29.01.2008Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
29.01.2008BJC 2008; 98:300-8
Strasser Florian, Cerny Thomas, Von Moss Roger, Brändle Michael, Holst B, Kaufmann K, Tschöp M, Büche Daniel, Thürlimann Beat, Maeder Micha, Lutz T A, Demmer-Steingruber Ruth
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
Bernhard J, Coates A, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Colleoni M, Green M, Thürlimann B, Yeo W, Aebi S, Forbes J, Hürny C, Basser R, Martinelli G, Zhang J, Zahrieh D, International Breast Cancer Study Group. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. BJC 2008; 98:25-33.
15.01.2008Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
15.01.2008BJC 2008; 98:25-33
Bernhard J, Coates A S, Goldhirsch A, Price K N, Castiglione-Gertsch M, Gelber R D, Colleoni M, Green M D, Thürlimann Beat, Yeo W, Aebi S, Forbes J F, Hürny C, Basser R, Martinelli G, Zhang J J, Zahrieh D, International Breast Cancer Study Group
Adjuvante Chemotherapie: Die Indikation zur Behandlung im Wandel
Ruhstaller T. Adjuvante Chemotherapie: Die Indikation zur Behandlung im Wandel. Hausarztpraxis 2008; 13:14-15.
01.01.2008Adjuvante Chemotherapie: Die Indikation zur Behandlung im Wandel
01.01.2008Hausarztpraxis 2008; 13:14-15
Ruhstaller Thomas
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Rasmussen B, Altermatt H, Gelber R, Castiglione-Gertsch M, Goldhirsch A, Gusterson B, Thürlimann B, Coates A, Viale G, Braye S, Lacroix-Triki M, Regan M, Lykkesfeldt A, Dell'Orto P, Del Curto B, Henriksen K, Mastropasqua M, Price K, Méry E, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. The Lancet 2008; 9:23-8.
01.01.2008Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
01.01.2008The Lancet 2008; 9:23-8
Rasmussen Birgitte B, Altermatt Hans J, Gelber Richard D, Castiglione-Gertsch Monica, Goldhirsch Aron, Gusterson Barry A, Thürlimann Beat, Coates Alan S, Viale Giuseppe, Braye Stephen, Lacroix-Triki Magali, Regan Meredith M, Lykkesfeldt Anne E, Dell'Orto Patrizia, Del Curto Barbara, Henriksen Katrine L, Mastropasqua Mauro G, Price Karen N, Méry Eliane, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Translationale Forschung beim Mammakarzinom- Workshop zur Erarbeitung neuer Forschungsideen im Rahmen des Biedenkopfsymposiums Xlll der Banss-Stiftung
von Minkwitz G, Thomssen C, Schrauder M, Roller M, Rody A, Niederacher D, Müller M, Martin B, Loibl S, Lenhard M, Momor M, Karn T, Huober J, Harbeck N, Groner B, Eidtmann H, Kaufmann M. Translationale Forschung beim Mammakarzinom- Workshop zur Erarbeitung neuer Forschungsideen im Rahmen des Biedenkopfsymposiums Xlll der Banss-Stiftung. Geburtsh Frauenheilk 2008; 68:1160-1165.
01.01.2008Translationale Forschung beim Mammakarzinom- Workshop zur Erarbeitung neuer Forschungsideen im Rahmen des Biedenkopfsymposiums Xlll der Banss-Stiftung
01.01.2008Geburtsh Frauenheilk 2008; 68:1160-1165
von Minkwitz G, Thomssen C, Schrauder M, Roller M, Rody A, Niederacher D, Müller M, Martin B, Loibl S, Lenhard M, Momor M, Karn T, Huober Jens, Harbeck N, Groner B, Eidtmann H, Kaufmann M
Primäre und adjuvante Systemtheraphie des operablen Mammakarzinoms
Thomssen C, Huober J. Primäre und adjuvante Systemtheraphie des operablen Mammakarzinoms. Onkologe 2008; 14:504-513.
01.01.2008Primäre und adjuvante Systemtheraphie des operablen Mammakarzinoms
01.01.2008Onkologe 2008; 14:504-513
Thomssen C, Huober Jens
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
Mouridsen H, Price K, Smith I, Colleoni M, Gelber R, Paridaens R, Forbes J, Mauriac L, Thürlimann B, Sun Z, Castiglione-Gertsch M, Rabaglio M, Coates A, Keshaviah A, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. JCO 2007; 25:5715-22.
20.12.2007Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
20.12.2007JCO 2007; 25:5715-22
Mouridsen Henning, Price Karen N, Smith Ian, Colleoni Marco, Gelber Richard D, Paridaens Robert, Forbes John F, Mauriac Louis, Thürlimann Beat, Sun Zhuoxin, Castiglione-Gertsch Monica, Rabaglio Manuela, Coates Alan S, Keshaviah Aparna, Goldhirsch Aron
Endocrine symptom assessment in women with breast cancer: what a simple "yes" means
Ribi K, Bernhard J, Rufibach K, Thürlimann B, von Moos R, Ruhstaller T, Glaus A, Böhme C. Endocrine symptom assessment in women with breast cancer: what a simple "yes" means. JSCC 2007; 15:1349-56.
01.12.2007Endocrine symptom assessment in women with breast cancer: what a simple "yes" means
01.12.2007JSCC 2007; 15:1349-56
Ribi K, Bernhard J, Rufibach K, Thürlimann Beat, von Moos R, Ruhstaller Thomas, Glaus A, Böhme C
Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine
Reichmann U, Bokemeyer C, Wallwiener D, Bamberg M, Huober J. Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007; 18:1981-4.
01.12.2007Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine
01.12.2007Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007; 18:1981-4
Reichmann U, Bokemeyer C, Wallwiener D, Bamberg M, Huober Jens
Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut)
du Bois A, Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom, Kölbl H, Jackisch C, Stähle A, Burges A, Wimberger P, Huober J, Loibl S, Burchardi N, Pfisterer J, Kommission Uterus. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecologic oncology 2007; 107:518-25.
01.12.2007Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut)
01.12.2007Gynecologic oncology 2007; 107:518-25
du Bois A, Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom, Kölbl H, Jackisch C, Stähle A, Burges A, Wimberger P, Huober Jens, Loibl S, Burchardi N, Pfisterer J, Kommission Uterus
Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome
Knauer M, Haid A, Ammann K, Lang A, Offner F, Türtscher M, Cerkl P, Wenzl E. Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome. World J Surg Oncol 2007; 5:114.
11.10.2007Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome
11.10.2007World J Surg Oncol 2007; 5:114
Knauer Michael, Haid Anton, Ammann Karlheinz, Lang Alois, Offner Felix, Türtscher Martina, Cerkl Peter, Wenzl Etienne
Standardization of pathologic complete response rates in breast cancer treatment
Knauer M, Devries A, Wenzl E, Haid A. Standardization of pathologic complete response rates in breast cancer treatment. Breast Cancer Res Treat 2007; 110:395-6.
13.09.2007Standardization of pathologic complete response rates in breast cancer treatment
13.09.2007Breast Cancer Res Treat 2007; 110:395-6
Knauer Michael, Devries Alexander, Wenzl Etienne, Haid Anton
Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?
Ruhstaller T, Thürlimann B, Köberle D, von Moos R. Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?. JCO 2007; 25:4025-6; author reply 4026-7.
01.09.2007Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?
01.09.2007JCO 2007; 25:4025-6; author reply 4026-7
Ruhstaller Thomas, Thürlimann Beat, Köberle Dieter, von Moos Roger
Reducing the risk of early recurrence in hormone-responsive breast cancer
Thürlimann B. Reducing the risk of early recurrence in hormone-responsive breast cancer. Ann Oncol 2007; 18 Suppl 8:viii8-17.
01.09.2007Reducing the risk of early recurrence in hormone-responsive breast cancer
01.09.2007Ann Oncol 2007; 18 Suppl 8:viii8-17
Thürlimann Beat
Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001)
Hartmann J, Grünwald V, Kanz L, Käfer G, Pintoffl J, Meisinger I, Huober J, Horger M, Schleicher J, Mayer F, German sarcoma group. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer 2007; 110:861-6.
15.08.2007Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001)
15.08.2007Cancer 2007; 110:861-6
Hartmann Joerg T, Grünwald Viktor, Kanz Lothar, Käfer Gabriele, Pintoffl Jan, Meisinger Ines, Huober Jens, Horger Marius, Schleicher Jan, Mayer Frank, German sarcoma group